Investigating the impact of ramelteon on all-cause mortality in ischemic stroke ICU patients: a retrospective propensity-matched study from the MIMIC-IV database.

Naunyn Schmiedebergs Arch Pharmacol · 2026 · PMC12935770 · PMID 41037129

Europe PMC DOI

hedged sentence

0.0650

closest p · 1.3× alpha

0.0650

boldest claim

The sentences

did not reach statistical significanceP = 0.065so close (0.05 < p ≤ 0.1)

While patients in the 100–300 mg group also showed significant benefits for 28-day (HR = 0.29, 95% CI: 0.15–0.56, P < 0.001) and 90-day all-cause mortality (HR = 0.57, 95% CI: 0.39–0.84, P = 0.004), the association with 365-day all-cause mortality did not reach statistical significance (HR = 0.73, 95% CI: 0.52–1.02, P = 0.065).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.